
Biagio Ricciuti/X
May 11, 2025, 18:36
Biagio Ricciuti: Adjuvant/Neoadjuvant vs Perioperative Chemo-Immunotherapy in Resectable NSCLC at RomeLung25
Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer, shared a post on X:
“Thoughtful presentations by Federico Cappuzzo and Solange Peters dissecting pros and cons of adjuvant/neoadjuvant vs perioperative chemo-immunotherapy in resectable NSCLC at RomeLung25”
More posts featuring RomeLung25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 18:14
May 11, 2025, 18:05
May 11, 2025, 17:07
May 11, 2025, 16:57
May 11, 2025, 16:49